Longitudinal tau PET in ageing and Alzheimer’s disease

See Hansson and Mormino (doi:10.1093/brain/awy065) for a scientific commentary on this article. Where should measurements be taken to best capture tau accumulation in ageing and Alzheimer’s disease? Jack et al. report that in clinically symptomatic stages of Alzheimer’s disease, tau accumulation occurs throughout the brain, rather than only in specific areas. Rate measurements from simple meta-regions of interest may be sufficient to capture progressive within-person tau accumulation.

• Publication year

  2018

• Venue

  Brain : a journal of neurology

• Publication date

  2018-03-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/brain/awy059PMID 29538647PMCID 5917767
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease

  2018cited by this paper
• Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.

  2018cited by this paper
• Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer’s disease dementia

  2018cited by this paper
• PET Tau and Amyloid-beta Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers (vol 60, pg 283, 2017)

  2018cited by this paper
• Tau and β-Amyloid Are Associated with Medial Temporal Lobe Structure, Function, and Memory Encoding in Normal Aging

  2017cited by this paper
• Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity

  2017cited by this paper
• Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global &bgr;-Amyloid Burden

  2017cited by this paper
• Defining imaging biomarker cut points for brain aging and Alzheimer's disease

  2017cited by this paper
• AV‐1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure

  2017cited by this paper
• Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease

  2017cited by this paper
• PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers

  2017cited by this paper
• Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition

  2017cited by this paper
• Optimizing PiB‐PET SUVR change‐over‐time measurement by a large‐scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE

  2017cited by this paper
• Distinct 18F‐AV‐1451 tau PET retention patterns in early‐ and late‐onset Alzheimer's disease

  2017cited by this paper
• Reference Tissue–Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging

  2017cited by this paper
• A comparison of five partial volume correction methods for Tau and Amyloid PET imaging with [18F]THK5351 and [11C]PIB

  2017cited by this paper
• Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex

  2017cited by this paper
• 18F-Flortaucipir PET/MRI Correlations in Nonamnestic and Amnestic Variants of Alzheimer Disease

  2017cited by this paper
• Comparison of multiple tau‐PET measures as biomarkers in aging and Alzheimer's disease

  2017cited by this paper
• Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum.

  2017cited by this paper
• Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

  2016cited by this paper
• Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.

  2016cited by this paper
• In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum

  2016cited by this paper
• Tau positron emission tomographic imaging in aging and early Alzheimer disease

  2016cited by this paper
• PET Imaging of Tau Deposition in the Aging Human Brain.

  2016cited by this paper
• Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

  2016influential reference
• The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging.

  2016cited by this paper
• Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.

  2016cited by this paper
• The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

  2016cited by this paper
• Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly

  2016cited by this paper
• Tau imaging: early progress and future directions.

  2015cited by this paper
• Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease

  2015cited by this paper
• Improved Power for Characterizing Longitudinal Amyloid-β PET Changes and Evaluating Amyloid-Modifying Treatments with a Cerebral White Matter Reference Region

  2015cited by this paper
• Measurement of Longitudinal β-Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios

  2015cited by this paper
• The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET

  2015influential reference
• Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease

  2014cited by this paper
• The A4 Study: Stopping AD Before Symptoms Begin?

  2014cited by this paper
• Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

  2013cited by this paper
• Propagation of tau pathology in a model of early Alzheimer's disease.

  2012cited by this paper
• Trans-Synaptic Spread of Tau Pathology In Vivo

  2012cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup

  2011cited by this paper
• Ecology of the aging human brain.

  2011cited by this paper
• Alzheimer’s disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies

  2011cited by this paper
• The neuropathology of probable Alzheimer disease and mild cognitive impairment

  2009cited by this paper
• The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics

  2008cited by this paper
• Neuropathologic substrate of mild cognitive impairment.

  2006cited by this paper
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

  2004cited by this paper
• Mild cognitive impairment as a diagnostic entity

  2004cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• The Elements of Statistical Learning

  2003influential reference
• The Elements of Statistical Learning: Data Mining, Inference, and Prediction

  2001cited by this paper
• Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects.

  2000cited by this paper
• Frequency of stages of Alzheimer-related lesions in different age categories.

  1997cited by this paper
• Frequency of stages of Alzheimer-related lesions in different age categories.

  1997cited by this paper
• The short test of mental status. Correlations with standardized psychometric testing.

  1991cited by this paper
• Correction of PET Data for Partial Volume Effects in Human Cerebral Cortex by MR Imaging

  1990cited by this paper

• Longitudinal monitoring of tau aggregation in progressive supranuclear palsy with [18F]PI‐2620 PET

  2026cites this paper
• Sex-specific patterns in tau spreading throughout the Braak stages in the Alzheimer’s disease spectrum

  2026cites this paper
• Characterizing amyloid and tau positron emission tomography‐based stages across the clinical continuum

  2026cites this paper
• Spatial patterns of tau accumulation across the Alzheimer's disease spectrum

  2026cites this paper
• Utility of 18F-Florzolotau PET as a prognostic and monitoring biomarker in a memory clinic cohort

  2025cites this paper
• Longitudinal biomarker studies in human neuroimaging: capturing biological change of Alzheimer’s pathology

  2025cites this paper
• The Cognitive and Neuroimaging for Neurodegenerative Disorders Study (CogNID): design and initial findings from real-world clinical practice

  2025cites this paper
• Sex Differences in Longitudinal Tau-PET in Preclinical Alzheimer Disease: A Meta-Analysis.

  2025cites this paper
• New Research on Biomarkers in Alzheimer's Continuum.

  2025cites this paper
• Pragmatic algorithm for visual assessment of 4-Repeat tauopathies in [18F]PI-2620 PET Scans

  2025cites this paper
• Longitudinal tau aggregation, atrophy, and cognitive decline in Alzheimer's disease

  2025cites this paper
• Continuum of Core 1 Biomarkers in Preclinical Alzheimer’s Disease

  2025cites this paper
• Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials

  2025cites this paper
• Amyloid-β and tau deposition in traumatic brain injury: a study of Vietnam War veterans

  2025cites this paper
• Multimodal and longitudinal characterization of distinct tau and atrophy clusters in Alzheimer’s disease spectrum

  2025influential citation
• Integration of automatic MRI segmentation techniques with neuropsychological assessments for early diagnosis and prognosis of Alzheimer's disease. A systematic review

  2025cites this paper
• Air Pollution as a Key Risk Factor for Alzheimer’s Disease: A Comprehensive Review

  2025cites this paper
• The Dallas Lifespan Brain Study: A Comprehensive Adult Lifespan Data Set of Brain and Cognitive Aging

  2025cites this paper
• Development of a plasma biomarker diagnostic model as a screening strategy for Alzheimer's disease in older inpatients

  2025cites this paper
• Tau biomarkers for neurodegenerative diseases: Current state and perspectives.

  2025cites this paper
• petBrain: a new pipeline for amyloid, Tau tangles and neurodegeneration quantification using PET and MRI

  2025cites this paper
• Eligibility for donanemab trial in a population-based study of cognitive aging

  2025cites this paper
• Associations of Chronic Insomnia, Longitudinal Cognitive Outcomes, Amyloid-PET, and White Matter Changes in Cognitively Normal Older Adults.

  2025cites this paper
• The study of plaques and tangles makes few and inaccurate predictions about the main features of cognitive disorders: A narrative review

  2025cites this paper
• Delayed primacy recall in AVLT is associated with medial temporal tau PET burden in cognitively unimpaired adults.

  2025cites this paper
• The intrinsic connectivity between the default mode and dorsal attention networks is an independent fMRI biomarker of Alzheimer's disease pathology burden

  2025cites this paper
• Preclinical Alzheimer's and vascular biomarkers alter brain aging in cognitively normal adults: a MRI-based study

  2025cites this paper
• APOE ɛ4 carriership determines a faster plasma p‐tau217 progression in Aβ‐positive individuals

  2025cites this paper
• The evolving landscape of Alzheimer's disease therapy: From Aβ to tau.

  2025cites this paper
• Functional Neuroimaging in Clinical Neurology: A Comprehensive Review of Commonly Used Modalities

  2025cites this paper
• Top-down attention and Alzheimer’s pathology affect cortical selectivity during learning, influencing episodic memory in older adults

  2025cites this paper
• Divergent actions of physiological and pathological amyloid-β on synapses in live human brain slice cultures

  2025cites this paper
• Aretheus’un Tanımladığı Demans, Bugünkü Hali ile Alzheimer Hastalığının İnsan ve Köpeklerde Çift Yönlü Benzerlikleri

  2025cites this paper
• Developing a novel reference region for [18F]PI-2620-PET imaging to facilitate the assessment of 4-repeat tauopathies

  2025cites this paper
• Vascular β-amyloid potentially colocalises with phosphorylated tau in cerebral amyloid angiopathy

  2025cites this paper
• Establishing tau-PET cut-points for cognitive diagnosis with 18 F-PI-2620 in a multi-ethnoracial cohort

  2025cites this paper
• Depressive Symptoms Correlate With Tau Accumulation Rates in Amyloid Positive Adults.

  2025cites this paper
• The AROMHA brain health test is a remote olfactory assessment to screen for cognitive impairment

  2025cites this paper
• Variable and interactive effects of Sex, APOE ε4 and TREM2 on the deposition of tau in entorhinal and neocortical regions

  2025influential citation
• Cognitive and Neuroimaging for Neurodegenerative Disorders: A Cohort Study Design with Initial Findings

  2025cites this paper
• Annexin A6 membrane repair protein protects against amyloid-induced dystrophic neurites and tau phosphorylation in Alzheimer’s disease model mice

  2025cites this paper
• Accuracy of plasma biomarkers to detect Alzheimer's disease proteinopathy prior to dementia

  2025cites this paper
• Integrating visual assessments and quantification methods for tau PET staging

  2025cites this paper
• Imaging Synaptic Density in Aging and Alzheimer Disease with [18F]SynVesT-1

  2025cites this paper
• Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia

  2025cites this paper
• Novel Hyperbranched Rolling Circle Amplification-Driven Aptasensor for Ultrasensitive and Multiplex Biomarkers Detection of Alzheimer's Disease

  2025cites this paper
• Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease

  2025cites this paper
• Association between FDG- and TSPO-PET signals across human and animal studies investigating neurodegenerative conditions: a systematic review

  2025cites this paper
• Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer's disease

  2025cites this paper
• Predictive Value of Plasma Biomarkers in Tau‐PET Transitions

  2025cites this paper
• Neurobiological and neuroimaging biomarkers: A narrative review of precision medicine for diagnosing neurodegenerative disorders

  2025cites this paper
• The predictive role of olfactory identification on episodic memory and mild cognitive impairment: Results from the CIMA-Q cohort

  2025cites this paper
• Characterizing amyloid and tau PET-based stages across the clinical continuum

  2025cites this paper
• Implication for Clinical Trials From Longitudinal Tau-PET Accumulation Across Biological Alzheimer Disease Stages

  2025influential citation
• White matter hyperintensities and TDP‐43 pathology in Alzheimer's disease

  2025cites this paper
• Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

  2025cites this paper
• Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

  2025cites this paper
• Elevated CSF GAP-43 is associated with accelerated tau accumulation and spread in Alzheimer’s disease

  2024cites this paper
• Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology

  2024cites this paper
• Spatial transcriptomic patterns underlying amyloid-β and tau pathology are associated with cognitive dysfunction in Alzheimer’s disease

  2024cites this paper
• Longitudinal synaptic loss versus tau Braak staging in amnestic mild cognitive impairment

  2024cites this paper
• Artificial Intelligence-Based Methodologies for Early Diagnostic Precision and Personalized Therapeutic Strategies in Neuro-Ophthalmic and Neurodegenerative Pathologies

  2024cites this paper
• Neuroimaging in Dementia

  2024cites this paper
• Partial volume correction in longitudinal tau PET studies: is it really needed?

  2024influential citation
• Connectivity, Pathology, and ApoE4 Interactions Predict Longitudinal Tau Spatial Progression and Memory

  2024cites this paper
• Premenopausal bilateral oophorectomy and Alzheimer's disease imaging biomarkers later in life

  2024cites this paper
• Top-down attention and Alzheimer’s pathology impact cortical selectivity during learning, influencing episodic memory in older adults

  2024cites this paper
• A Lipid-Raft Theory of Alzheimer's Disease.

  2024cites this paper
• Identification of late-stage tau accumulation using plasma phospho-tau217

  2024cites this paper
• Microscopy assessment of a fluorescence [18F] flortaucipir analog (T726) shows neuropathological overlap with 3R and 4R tau lesions

  2024cites this paper
• [Erratum] Brain Imaging and neurostimulation in health and disorders: status report

  2024cites this paper
• Survey among experts on the future role of tau‐PET in clinical practice and trials

  2024cites this paper
• Investigating the feasibility of 18F‐flortaucipir PET imaging in the antemortem diagnosis of primary age‐related tauopathy (PART): An observational imaging‐pathological study

  2024cites this paper
• Modeling the progression of neuropsychiatric symptoms in Alzheimer's disease with PET-based Braak staging.

  2024cites this paper
• Variable and interactive effects of Sex, APOE ε4 and TREM2 on the deposition of tau in entorhinal and neocortical regions

  2024cites this paper
• Local molecular and connectomic contributions of tau-related neurodegeneration

  2024cites this paper
• Non-rapid eye movement sleep slow-wave activity features are associated with amyloid accumulation in older adults with obstructive sleep apnoea

  2024cites this paper
• AROMHA Brain Health Test: A Remote Olfactory Assessment as a Screen for Cognitive Impairment

  2024cites this paper
• Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort

  2024cites this paper
• BACE1 Inhibitors for Alzheimer’s Disease: Current Challenges and Future Perspectives

  2024cites this paper
• Complex relationships of socioeconomic status with vascular and Alzheimer’s pathways on cognition

  2024cites this paper
• Protein fibril aggregation on red blood cells: a potential biomarker to distinguish neurodegenerative diseases from healthy aging

  2024cites this paper
• Temporal progression of tau pathology and neuroinflammation in a rhesus monkey model of Alzheimer's disease

  2024cites this paper
• Recent advances in nanoenzymes for Alzheimer's disease treatment.

  2024cites this paper
• Multimodal cross‐examination of progressive apraxia of speech by diffusion tensor imaging‐based tractography and Tau‐PET scans

  2024cites this paper
• Microglia either promote or restrain TRAIL-mediated excitotoxicity caused by Aβ1−42 oligomers

  2024cites this paper
• Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

  2024cites this paper
• Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.

  2024cites this paper
• Linking white matter hyperintensities to regional cortical thinning, amyloid deposition, and synaptic density loss in Alzheimer's disease

  2024cites this paper
• [18F]PI-2620 Tau PET signal across the aging and Alzheimer’s disease clinical spectrum

  2024cites this paper
• Differential Synaptic Loss in β‐Amyloid Positive Versus β‐Amyloid Negative Corticobasal Syndrome

  2024cites this paper
• Generating PET scan patterns in Alzheimer’s by a mathematical model

  2024cites this paper
• Evaluation of partial volume correction and analysis of longitudinal [18F]GTP1 tau PET imaging in Alzheimer's disease using linear mixed-effects models

  2024cites this paper
• Imaging synaptic density in ageing and Alzheimer’s Disease with [18F]-SynVesT-1

  2024cites this paper
• Association of Basal Forebrain Volume with Amyloid, Tau, and Cognition in Alzheimer’s Disease

  2024cites this paper
• Modulation of contextual fear acquisition and extinction by acute and chronic relaxin-3 receptor (RXFP3) activation in the rat retrosplenial cortex.

  2024cites this paper
• Tau-PET in early cortical Alzheimer brain regions in relation to mild behavioral impairment in older adults with either normal cognition or mild cognitive impairment

  2024cites this paper
• Biomarker-based staging of Alzheimer disease: rationale and clinical applications

  2024cites this paper
• Comparison of cerebrospinal fluid, plasma and neuroimaging biomarker utility in Alzheimer’s disease

  2024cites this paper
• Deconstructing pathological tau by biological process in early stages of Alzheimer disease: a method for quantifying tau spatial spread in neuroimaging

  2024cites this paper